Found: 8
Select item for more details and to access through your institution.
KIR<sub>3</sub>DL<sub>2</sub> expression in patients with adult T-cell lymphoma/leukaemia.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
KIR3 DL2 ( CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
- Published in:
- British Journal of Dermatology, 2016, v. 175, n. 2, p. 325, doi. 10.1111/bjd.14626
- By:
- Publication type:
- Article
MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE‐TYPE AND IS A THERAPEUTIC TARGET IN ADULT T‐CELL LEUKEMIA/LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 271, doi. 10.1002/hon.82_2630
- By:
- Publication type:
- Article
KIR3DL2 IS EXPRESSED IN PERIPHERAL T‐CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 204, doi. 10.1002/hon.21_2630
- By:
- Publication type:
- Article
MEMBRANE EXPRESSION OF NK RECEPTOR KIR3DL2 CONTRIBUTES TO DELINEATE THE ACUTE‐TYPE AND IS A THERAPEUTIC TARGET IN ADULT T‐CELL LEUKEMIA/LYMPHOMA.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 271, doi. 10.1002/hon.82_2630
- By:
- Publication type:
- Article
KIR3DL2 IS EXPRESSED IN PERIPHERAL T‐CELL LYMPHOMAS AND MAY BE A THERAPEUTIC TARGET.
- Published in:
- Hematological Oncology, 2019, v. 37, p. 204, doi. 10.1002/hon.21_2630
- By:
- Publication type:
- Article
NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 44, doi. 10.1002/hon.2437_26
- By:
- Publication type:
- Article
Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results.
- Published in:
- Hematological Oncology, 2017, v. 35, p. 48, doi. 10.1002/hon.2437_31
- By:
- Publication type:
- Article